Clinical trial

The Effect of Intravenous Infusion of Labetalol Versus Hydralazine on Cerebral Hemodynamics of Preeclampsia Patients Prospective Randamized Study

Name

36264PR589/3/24

Description

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Trial arms

Trial start

2024-04-01

Estimated PCD

2024-09-01

Trial end

2024-09-01

Status

Active (not recruiting)

Phase

Early phase I

Treatment

Labetalol Injection

Labetalol intravenous infusion 20ml/hr

Arms:

Labetalol group

HydrALAZINE Injection

Hydralazine intravenous infusion 5mg/hr

Arms:

Hydralazine group

Size

Primary endpoint

Cerebral blood flow

Pre intervention-after one hour of intervention

Eligibility criteria

Inclusion Criteria: * patient with clinical diagnosis of sever preeclampsia Exclusion Criteria: Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion -

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}

Updated at

2024-04-11

1 organization

2 products

1 indication

Organization

Product

Indication

Product